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ABSTRACT
Interleukin-2 (IL2) is a cytokine that can stimulate cytotoxic immune cells 
to attack infected and malignant cells. Unfortunately, IL2 can also cause serious 
immune-related toxicity. Recently, a mutant of IL2 (IL2v) with abolished CD25 
binding, increased plasma half-life and less toxicity was engineered. Unlike wild-type 
IL2 (wt-IL2), mutant IL2v does not bind to the α-subunit (CD25) of the high affinity 
IL2αβγ receptor, but only to its β and γ subunit. Here, we investigated the biological 
properties of IL2v and compared with the wt-IL2 using fluorine-18 and PET. [18F]FB-
IL2v binds specifically to IL2 receptors (IL2R) on activated human peripheral blood 
monocytes (hPBMCs) and is cleared mainly by the kidneys (Balb/c mice). [18F]FB-IL2v 
PET studies in SCID mice injected with hPBMCs revealed high uptake in the implant 
(0.85 ± 0.15 SUV), which was significantly reduced after pretreatment with wt-IL2 
or mutant IL2v (SUV 0.26 ± 0.1 and 0.46 ± 0.1, p < 0.01). Compartment modeling 
and Logan graphical analysis in wistar rats inoculated with hPBMCs indicated that the 
binding of [18F]FB-IL2v to IL2R was reversible. The volume of distribution (VT) and 
the non-displaceable binding potential (BPnd) of mutant [18F]FB-IL2v in the implant 
were approximately 3 times lower than those of wild-type [18F]FB-IL2 (p < 0.01). 
Pretreatment with wt-IL2 significantly reduced the VT and BPnd of mutant [18F]FB-
IL2v in the implant (p < 0.001). This demonstrates that wild-type [18F]FB-IL2 binds 
stronger to IL2R and has faster kinetics than [18F]FB-IL2v, which makes it less 
suitable as a therapeutic drug. [18F]FB-IL2v, on the other hand, seems to have better 
properties for use as a therapeutic drug.
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INTRODUCTION
Interleukin 2 (IL2) is a 15 kDa cytokine that plays 
an important role in both cellular and hormone-mediated 
immune response [1–3]. Its primary function involves 
stimulation of growth, proliferation, activation and 
differentiation of T lymphocytes. IL2 does not only have 
a stimulatory effect on T lymphocytes, but also on several 
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other immune cells, such as lymphokine-activated killer 
cells, natural killer cells, monocytes and macrophages 
[4]. IL2 produces its effects through surface bound IL2 
receptors, which in the high affinity receptor consist of 
three receptors subunits: α (CD25), β (CD122), and γ 
(CD132). Both the β and γ subunit of the receptors are 
essential for signal transduction, whereas α and β subunit 
contain the binding site for IL2 [5–7] and the α chain acts 
as adaptor molecule in the high affinity receptor. 
Tumors have the ability to protect themselves from 
destruction by the immune system by inhibiting tumor-
infiltrating CD8+ effector cells. IL2 can reactivate these 
quiescent immune cells and stimulate them to destroy 
the cancer cells. As a result, wild type IL2 (aldesleukin, 
Proleukin®) has been approved as a drug for treatment of 
metastatic renal cell carcinoma and malignant melanoma 
[8]. However, a major drawback of the drug is that IL2 
is associated with significant toxicity, such as myocardial 
infarction, vascular leak syndrome, renal failure and 
neuropathy [9–11]. These side effects can be ascribed 
to activation of immune cells in other tissues than the 
tumor. Local administration of IL2 was shown to be 
highly effective in controlling malignant melanoma, but 
remission was observed after withdrawal of IL2 therapy 
[12]. Taken together these results suggest that IL2 has 
potential as an anti-cancer treatment by activation of 
tumor targeting immune cells, but its use in the clinic has 
been greatly hampered by its toxicity profile, especially 
when it was administered systemically.
To overcome these obstacles, scientists have 
created fusion proteins of IL2 linked to a tumor-targeting 
monoclonal antibody [13–16]. These IL2 fusion proteins 
are aimed to accumulate tissue-specifically in the tumor, 
resulting in an increased cytokine concentration inside the 
tumor and thus better anti-tumor activity [17]. However, 
these modified IL2 fusion proteins display slower plasma 
clearance than naïve IL2 and can cause significant 
activation of T cells outside the tumor and consequently 
they can still cause toxicity. In addition, the modified IL2 
proteins have a strong binding affinity (in the picomolar 
range) towards CD25. Since CD25 is also expressed on 
the vascular endothelium cells, the fusion proteins can also 
contribute to e.g. pulmonary toxicity [18]. 
Another drawback of IL2 as an immune-modulatory 
drug is that CD25 is not only expressed by NK cells and 
CD8+ effector T cells, but also by regulatory T cells (Treg). 
Thus, IL2 can also activate CD4+CD25+Foxp3+ lymphocytes, 
which are capable of suppressing the T cell-mediated 
anti-tumor activity. Upon activation, CD4+CD25+Foxp3+ 
expressing T cells stimulate the secretion of transforming 
growth factor β (TGF-β), which acts directly on the cytotoxic 
T cells and convert them into Treg cells. Because of the 
activation of Treg cells in the tumor, IL2 treated patients 
paradoxically may not necessarily show improved efficacy, 
even though there is a profound increase in the number of 
cytotoxic T cells at the tumor site [19]. 
To address these issues, genetically engineered 
IL2 variants have been developed that should produce 
less systemic toxicity, but may still be applicable in 
immunotherapy for solid tumors. Recently, a new 
monomeric engineered mutant of IL2, called IL2v, was 
developed for use in antibody-cytokine fusion proteins 
(immunocytokines), such as CEA-IL2v [20–21]. This 
mutant IL2v has abolished binding affinity for CD25 
and consequently shows reduced induction of Treg [22]. 
However, the capacity of IL2v to activate and expand NK 
and CD8+ effector T cells through binding to the β subunit 
of the IL2 receptor was retained [22]. 
The purpose of this study was to investigate the 
pharmacokinetic and binding properties of this monomeric 
naked IL2v (mutant IL2v) and compare them with those 
of wild type IL2. For this purpose, mutant IL2v and 
wild-type IL2 were radiolabeled with fluorine-18 for 
in-vivo imaging studies with positron emission tomography 
(PET). The behavior of the labeled mutant IL2v was 
investigated in rodents, bearing implants of activated 
human peripheral blood mononuclear cells (PBMCs)
RESULTS
Radiolabeling 
[18F]SFB was produced in a good radiochemical 
yield (38–45%) and radiochemical purity (94–98%), as 
determined by UPLC. Mutant [18F]FB-IL2v was produced 
by conjugation of [18F]SFB to mutant IL2v. The overall 
yield of the product varied from 3–15 %, depending on 
the purity of the synthon [18F]SFB. The purity of the tracer 
after purification with a PD10 cartridge was always >98% 
based on the UPLC, radio-TLC and TCA precipitation 
methods. UPLC analysis showed that the retention time of 
the mutant [18F]FB-IL2v (9.6 min) was a little longer than 
observed for native IL2v (9.4 min), which is likely due 
to the introduction of the label. Based on the Nanodrop 
spectrophotometric analysis of the protein concentration, 
the specific activity of the protein was approximately 
50,000 MBq/mg. 
In-vitro binding and stability 
The stability of mutant [18F]FB-IL2v was tested in 
PBS and in rat plasma using the TCA precipitation assay 
(Figure 1). In PBS, 93 ± 2% of mutant [18F]FB-IL2v was 
still intact after 1 h of incubation at 37°C. In rat plasma, 
88 ± 2% of the radiopharmaceutical was still intact after 
1 h of incubation. Thus, the labeled protein is sufficiently 
stable for in-vitro binding assays and in-vivo imaging 
studies. 
In order to assess in-vitro receptor binding, 
Phytohaemagglutinin (PHA) activated and non-activated 
human PBMCs were incubated with mutant [18F]FB-IL2v 
at 37°C for 30 min. PHA strongly activates human PBMCs, 
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resulting in a strong induction of the expression of IL2 
receptors (data not shown). As a result, mutant [18F]FB-
IL2v binding to PHA-activated PBMCs was 6-fold higher 
than binding to non-activated human PBMCs (8.7 ± 0.8 
vs 1.5 ± 0.5 %ID/106 cells, p < 0.001, Figure 2). To check 
whether binding of mutant [18F]FB-IL2v was specifically 
mediated by IL2 receptors, a blocking experiment was 
performed, in which activated human PBMCs were pre-
incubated with wild type IL2 or mutant IL2v (2 ng/ml). 
Saturation of IL2 receptors by pretreatment with wild-type 
IL2 resulted in an almost 3-fold decrease in the cellular 
binding of mutant [18F]FB-IL2v (8.7 ± 0.8 vs 3.1 ± 0.7 
%ID/106 cells, p < 0.01). Pretreatment with mutant IL2v 
also led to a significant reduction in cellular binding (8.7 
± 0.8 vs 4.7 ± 0.6 %ID/106 cells, p < 0.05), although 
the reduction in binding was smaller than observed for 
pretreatment with wild-type IL2 (Figure 2). 
Ex-vivo biodistribution 
Ex-vivo biodistribution of [18F]FB-IL2v was 
performed in healthy Balb/c mice at 15, 60 and 90 min 
post injection. The results of the study are presented in 
Table 1. In most tissues, trace uptake was highest at 60 
min after radiopharmaceutical injection. At each time 
point, highest radiopharmaceutical uptake was observed 
in the kidneys and urine, which suggests that the 
radiopharmaceutical is cleared through the urinary tract. 
Secondary lymphoid tissues, such as spleen, bone marrow 
and lymph nodes, showed moderately high tracer uptake 
(SUV > 0.5). Stomach, pancreas, heart, colon, and bone 
showed low uptake (SUV < 0.2). The uptake in bone did 
not increase over time, which indicates that defluorination 
of the radiopharmaceutical in-vivo was negligible. 
Ex-vivo biodistribution analysis in Wistar rats 
with a human PBMC implant showed a significantly 
higher uptake of wild-type [18F]FB-IL2 in the implant at 
80 min after radiopharmaceutical injection than uptake 
of mutant [18F]FB-IL2v (1.49 ± 0.66 vs 0.78 ± 0.19, 
p < 0.05). Similarly, plasma uptake showed a statistically 
significant difference between mutant [18F]FB-IL2v 
and wild-type [18F]FB-IL2 (8.94 ± 2.35 vs 4.93 ± 1.42, 
p < 0.05). Pretreatment with wild-type IL2 caused a 
significant reduction in the uptake of mutant [18F]FB-
IL2v in the implant of human PBMCs (0.78 ± 0.19 vs 
0.45 ± 0.18, p < 0.05). Pretreatment with wild-type 
IL2 resulted in an increased plasma concentration of 
mutant [18F]FB-IL2v (8.94 ± 2.35 vs 10.06 ± 0.82, 
p < 0.05). Pretreatment with wild-type IL2 also caused 
a slight reduction in mutant [18F]FB-IL2v uptake in 
other organs, but these differences were not statistically 
significant between groups for any organ (Table 2). 
PET imaging
Mutant [18F]FB-IL2v PET imaging studies were 
performed in SCID mice bearing an implant of activated 
human PBMCs. The uptake of the radiopharmaceutical 
in the human PBMC implant could already be visualized 
in the 15–30 min post injection PET images (Figure 
3A). Surprisingly, background uptake in major organs 
was high. Analysis of the mutant [18F]FB-IL2v TACs in 
the implant showed that the radiopharmaceutical uptake 
increased over time until the end of the scan (Figure 3C). 
In mice pretreated with either wild-type IL2 or mutant 
IL2v, mutant [18F]FB-IL2v uptake in the implants was 
significantly reduced (SUV at 25–30 min: control 0.68 
± 0.01; wild-type IL2 pretreated 0.25 ± 0.02, p < 0.01; 
Figure 1: In-vitro stability of mutant [18F]FB-IL2v in rat plasma and PBS. The radiopharmaceutical was incubated at 37°C for 
up to 90 min. The percentage of intact tracer was determined by the trichloroacetic acid precipitation assay. Data are presented as the mean 
of three independent experiments. Error bars represent the standard deviations. 
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mutant IL2v pretreated 0.40 ± 0.0.02, p < 0.05). Likewise, 
the area under the curve (AUC) in control animals (18.5 
± 1.1 min) was significantly higher than the AUC of 
the mice pretreated with wild-type IL2 (6.5 ± 0.95 min, 
p < 0.01) or mutant IL2v (11.5 ± 0.8 min, p < 0.05). 
PET imaging data were confirmed by ex-vivo 
measurement of the radioactivity in the implant at 50 
min after radiopharmaceutical injection. Ex-vivo analysis 
showed that radiopharmaceutical uptake (SUV) in the 
implant was significantly reduced by pretreatment with 
either wild-type IL2 or mutant IL2v (SUV: control 0.85 ± 
0.15; wild-type IL2 pretreated 0.26 ± 0.1, p < 0.01; mutant 
IL2v pretreated 0.46 ± 0.1, p < 0.05). Thus, a higher 
reduction in radiopharmaceutical uptake was observed 
after pretreatment with wild-type IL2 than with mutant 
IL2v (Figure 3B). Remarkably, also background levels of 
radioactivity were markedly reduced by pretreatment of 
the SCID mice with wild-type IL2 or mutant IL2v, which 
could suggest an effect on radiopharmaceutical clearance.
Metabolite analysis in plasma and urine
In-vivo metabolite analysis of the two labeled 
proteins in rats with PBMC implants was studied by 
means of the TCA precipitation assay. Both proteins 
were found to be stable in vivo, as 88 ± 6% of wild-type 
[18F]FB-IL2 and 87 ± 4% of mutant [18F]FB-IL2v in 
plasma was still intact at 60 min after tracer injection. Pre-
treatment with wild-type IL2 did not significantly affect 
the rate of mutant [18F]FB-IL2v metabolism (89 ± 4% at 
60 min) (Figure 4A). Analysis of urine samples collected 
80 min after radiopharmaceutical injection showed only 
degradation products in all the groups (Figure 4B).
Tracer kinetics in rats
Analysis of mutant [18F]FB-IL2v plasma kinetics 
was performed in Wistar rats with an implant of PHA-
activated hPBMCs and compared to radiolabeled wild-type 
[18F]FB-IL2. The kinetics of both radiopharmaceuticals in 
metabolite-corrected plasma are presented in Figure 5A. 
A rapid, bi-exponential plasma clearance was observed 
for both labeled proteins with half-lifes of 0.7 ± 0.2 min 
(17%) and 7.1 ± 2.6 min (83%) for wild-type [
18F]FB-IL2 
and 2.1 ± 1.3 min (14%) and 17.6 ± 1.3 min (86%) for 
mutant [18F]FB-IL2v. The difference in distribution half-
life (T1) between the two radiopharmaceuticals was not 
statistically significant. However, the clearance half-life 
(T2) of mutant [18F]FB-IL2v was significantly longer 
(p < 0.01), than that of wild-type [18F]FB-IL2. 
Pretreatment with wild-type IL2 (5 mg/kg), significantly 
increased the clearance half-life of mutant [18F]FB-IL2v 
(T1: 1.1 ± 0.6 min (14%), p < 0.292 and T2: 38.2 ± 1.6 
min (86%), p < 0.01) (Table 3). Similarly, the area under 
the plasma TAC of mutant [18F]FB-IL2v (751 ± 20 min) 
was a significantly higher (p < 0.05) than the AUC of 
Figure 2: In-vitro binding assay of mutant [18F]FB-IL2v to PHA-activated and non-activated human PBMCs. For 
blocking studies, cells were pre-incubated with 2 ng/ml of either wild-type IL2 or mutant IL2v, 30 min before tracer incubation at 4°C. 
All the experiments were performed in triplicate. Error bars represent the standard deviation. Statistically significant differences between 
non-activated and activated cells are indicated by $$$(p < 0.001). Significant differences between untreated activated PBMCs and activated 
PBMCs pretreated with wild-type IL2 or mutant IL2v are indicated by * (p < 0.05), ** (p < 0.01).
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wild-type [18F]FB-IL2 (618 ± 32 min). Pretreatment with 
wild type IL2 significantly increased the AUC of mutant 
[18F]FB-IL2v in plasma (864 ± 25 min, p < 0.01). 
The TACs of the radiolabelled proteins in human 
PBMC implants are shown in Figure 5B. The TACs of both 
radiopharmaceuticals were comparable at early time points. 
However, from 20 min after radiopharmaceutical injection 
onward, wild-type [18F]FB-IL2 showed a significantly 
higher uptake in the implant than mutant [18F]FB-IL2v 
(p < 0.05). Pretreatment with wild-type IL2 induced a 
significant reduction in mutant [18F]FB-IL2v uptake in the 
implant from 25 min after radiopharmaceutical injection 
until the end of the scan (p < 0.05). 
Pharmacokinetic modeling 
The 2-tissue reversible compartment model 
(2TRCM) was used to fit the kinetic data from the VOI of 
the exogenous human PBMC implant, using the metabolite-
corrected plasma curves as input functions. The VT of the 
implant of wild-type [18F]FB-IL2 and mutant [18F]FB-IL2v, 
as calculated with the 2TRCM, were comparable to those 
determined by Logan graphical analysis (Table 3). The 
VT of wild-type [
18F]FB-IL2 was approximately 2 times 
higher than the VT of mutant [
18F]FB-IL2v (p < 0.01). 
Pretreatment with wild-type IL2 resulted in a 3-fold 
reduction in the VT of mutant [
18F]FB-IL2v in the implant 
(p < 0.001), suggesting that tracer uptake is mediated by the 
IL2 receptor. Also the BPnd (=k3/k4) in the implant showed 
a significant difference between wild-type [18F]FB-IL2 and 
mutant [18F]FB-IL2v (10.6 ± 2.9 vs. 4.3 ± 0.5, p < 0.001). 
Pretreatment with wild-type IL2 significantly reduced the 
BPnd of mutant [
18F]-IL2v (2.2 ± 0.6, p < 0.001). 
The kinetics of both wild-type [18F]FB-IL2 and 
mutant [18F]FB-IL2v in the human PBMC implant 
could be better described by Logan graphical analysis 
(R2 = 0.98) than by Patlak analysis (R2 = 0.54), confirming 
that both radiopharmaceuticals show reversible binding. 
Logan graphical analysis was used to calculate the VT 
in the implant (Table 3). Wild-type [18F]FB-IL2 showed 
a significantly higher VT in the implant than mutant [
18F]
FB-IL2v (2.5-fold, p < 0.01). Pretreatment with wild-type 
IL2 significantly reduced the VT of mutant [
18F]FB-IL2v 
in the implant (2-fold, p < 0.001). 
Table 1: Ex-vivo biodistribution data of [18F]FB-IL2v in healthy Balb/c mice
Organs 15 min 60 min 90 min
Total Blood 0.34 ± 0.12 0.42 ± 0.15 0.29 ± 0.13
Plasma 0.66 ± 0.39 0.63 ± 0.31 0.38 ± 0.19
Heart 0.22 ± 0.25 0.18 ± 0.10 0.11 ± 0.06
Lung 0.44 ± 0.13 0.28 ± 0.12 0.18 ± 0.08
Thymus 0.22 ± 0.17 0.21 ± 0.08 0.21 ± 0.11
Adrenal gland 0.54 ± 0.21 0.42 ± 0.16 0.50 ± 0.30
Kidney 5.33 ± 1.14 7.16 ± 1.63 2.41 ± 0.47
Liver 0.71 ± 0.26 0.62 ± 0.28 0.33 ± 0.15
Stomach 0.11 ± 0.09 0.19 ± 0.07 0.14 ± 0.04
Pancreas 0.12 ± 0.09 0.18 ± 0.05 0.18 ± 0.08
Spleen 0.41 ± 0.11 0.52 ± 0.16 0.17 ± 0.06
Duodenum 0.19 ± 0.10 0.21 ± 0.17 0.38 ± 0.20
Colon 0.24 ± 0.12 0.15 ± 0.02 0.18 ± 0.05
Ileum 0.31 ± 0.14 0.28 ± 0.12 0.24 ± 0.12
Muscle 0.22 ± 0.15 0.42 ± 0.28 0.15 ± 0.04
Fat tissues 0.32 ± 0.14 0.62 ± 0.35 0.33 ± 0.12
Bone 0.11 ± 0.08 0.12 ± 0.05 0.08 ± 0.04
Bone marrow 0.49 ± 0.25 1.21 ± 0.51 0.27 ± 0.13
Brain 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01
Salivary gland 0.18 ± 0.05 0.14 ± 0.04 0.11 ± 0.03
Lymph Node 0.23 ± 0.13 0.58 ± 0.09 0.14 ± 0.12
All mice were injected with [18F]FB-IL2v via the penile vein and kept under anesthesia. After 15, 60 and 90 min (n = 5), 
animals were sacrificed and different organs were collected and weighed. Tracer uptake was expressed as standardized 
uptake values (SUV). All data represent the mean ± standard deviation.
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DISCUSSION
In this study, we evaluated the binding and kinetic 
properties of a monomeric mutant interleukin-2 (IL2v). 
For this purpose, mutant IL2v was labeled with 18F in 
3–15% radiochemical yield. To improve the labeling yield, 
the effect of pH, the amount of protein, and the volume 
of the reaction mixture were investigated. The maximum 
labeling yield was obtained at pH 8.5 and further increase 
or decrease in the pH resulted in lower radiochemical 
yields. This might be due to competing hydrolysis of [18F]-
SFB at higher pH and protonation of the amino groups 
in the lysine residues at lower pH, both effects resulting 
in a low conjugation rate. The amount of protein was 
varied from 50 µg to 300 µg per labeling. The overall 
yield was increased as the concentration of the protein 
was increased. However, to reduce costs and to obtain 
sufficiently high specific activities, only 200 µg of IL2v 
was used for labeling for in-vitro and in-vivo studies. The 
total volume of the reaction mixture was varied between 
0.3 mL and 1 mL. The radiochemical yield increased 
as the volume of the reaction mixture was reduced and 
consequently the protein concentration was increased. 
Overall, the optimal conjugation conditions for labeling 
of [18F]FB-IL2v were similar to those for labeling of wild-
type [18F]FB-IL2 [23].
To check the binding properties of mutant [18F]FB-
IL2v, an in-vitro assay was performed on human PBMCs. 
These cells will overexpress the high affinity IL2 receptors 
(α, β, and γ subunits) upon activation with PHA [25–26]. 
In line with the expression levels of the IL2 receptors, 
cellular binding of mutant [18F]FB-IL2v to activated 
human PBMCs was significantly higher than binding to 
non-activated cells. Specific binding of mutant [18F]FB-
IL2v to IL2 receptors on activated human PBMCs was 
confirmed by (partial) saturation of the receptors with 
a low concentration of wild-type IL2 or mutant IL2v, 
resulting in reduced cellular binding of [18F]FB-IL2v to 
PBMCs. Taken together, these results demonstrate that 
cellular uptake of mutant [18F]FB-IL2v is specifically 
mediated by the IL2 receptor.
The in-vitro stability of the tracer was tested both 
in plasma and in PBS. Mutant [18F]FB-IL2v was found 
to be quite stable in both media, although the tracer was 
Table 2: Ex-vivo biodistribution data of wild-type [18F]FB-IL2 and mutant [18F]FB-IL2v in Wistar rats inoculated with 






Mutant [18F]FB-IL2v + wild-
type IL2 (n = 4)
Total Blood 5.29 ± 2.17 5.73 ± 2.18 6.65 ± 0.68
Plasma 4.93 ± 1.42 8.94 ± 2.35* 10.06 ± 0.82*
Heart 1.32 ± 0.70 0.81 ± 0.47 1.33 ± 0.11
Lung 2.25 ± 1.09 1.78 ± 0.75 2.57 ± 0.45
Thymus 0.66 ± 0.08 0.41 ± 0.19 0.57 ± 0.13
Adrenal gland 1.63 ± 0.28 1.66 ± 0.96 1.78 ± 0.33
Kidney 16.06 ± 4.28 13.36 ± 5.63 12.85 ± 0.55
Liver 3.51 ± 1.5 2.45 ± 0.81 2.46 ± 0.53
Stomach 0.80 ± 0.10 0.79 ± 0.11 0.79 ± 0.15
Pancreas 0.89 ± 0.08 1.26 ± 0.34 0.94 ± 0.14
Spleen 4.12 ± 1.82 3.16 ± 1.04 2.35 ± 0.17
Duodenum 1.50 ± 0.23 2.15 ± 0.10 1.55 ± 0.39
Colon 0.91 ± 0.16 1.69 ± 0.12 0.65 ± 0.06
Ileum 1.07 ± 0.21 0.99 ± 0.63 0.83 ± 0.29
Normal Muscle 0.26 ± 0.09 0.47 ± 0.19 0.26 ± 0.10
Fat tissues 0.19 ± 0.03 0.82 ± 0.45 0.19 ± 0.06
Bone 0.63 ± 0.27 0.64 ± 0.26 0.60 ± 0.18
Bone Marrow 3.02 ± 0.90 2.63 ± 1.48 2.42 ± 0.14
Salivary gland 0.70 ± 0.08 0.67 ± 0.32 0.66 ± 0.07
Lymph Node (auxiliary) 1.13 ± 1.26 0.83 ± 0.28 0.73 ± 0.16
Xenografted (PBMCs) 1.49 ± 0.66 0.83 ± 0.20* 0.45 ± 0.18*
In one group, rats were injected with mutant [18F]FB-IL2v and pre-treated with wild type IL2 (5 mg/kg). All the data were 
converted into SUV, and represent the means ± standard deviations. statistical differences are indicated by *(p < 0.05).
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Figure 3: PET and ex-vivo biodistribution data of mutant [18F]FB-IL2v in SCID mice bearing an implant of PHA-
activated human PBMCs (n = 4). Control animals are compared to mice treated with 5 mg/kg (S.C) wild-type IL2 (IL2) or mutant 
IL2v prior to tracer injection. (A) Coronal PET images (25–30 min) of a control mouse and a mouse pretreated with wild-type IL2 
(Blocker). The arrow indicates the location of the implant. Ht signifies the location of the heart. (B) Ex-vivo tracer uptake of mutant [18F]
FB-IL2v in the PBMC implant 50 min after tracer injection. Tracer uptake was blocked with either wild-type IL2 or mutant IL2v. (C) PET-
derived time activity curves (TACs) of mutant [18F]FB-IL2v in the implant of control mice and mice that were pretreated with wild-type 
or mutant IL2. Significant differences between the pretreated groups and the untreated controls are indicated by *(p < 0.05), **(p < 0.01).
Figure 4: In-vivo metabolism of wild-type [18F]FB-IL2 and mutant [18F]FB-IL2v in Wistar rats, as determined by the 
TCA precipitation assay. (A) Blood samples were collected at different time points after tracer injection. Plasma was collected and 
subjected to the TCA precipitation assay and the percentage of intact tracer was determined. (B) Urine was collected from the bladder 80 
min after mutant [18F]FB-IL2v injection and the percentage of intact labelled protein was determined by means of the precipitation TCA 
assay. 
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slightly more stable in the PBS. This slight difference may 
be ascribed to some degradation of the protein in plasma 
by protease enzymes. The in-vivo stability of [18F]FB-IL2v 
was tested in mice (Balb/c and SCID) and rats (Wistar). In 
Wistar rats, the tracer remained largely intact in plasma for 
the duration of the PET scan (>87%, at 60 min) and similar 
results were found in mice. In contrast, only degradation 
products were found in urine samples. These data suggest 
that [18F]FB-IL2v is metabolized in the renal cortex and its 
metabolites are immediately excreted through urine, as is 
also the case for naïve IL2 [23].
Ex-vivo evaluation of [18F]FB-IL2v in healthy 
Balb/c mice showed that tracer uptake in most organs was 
highest at 60 min after tracer injection. In contrast, wild-
type [18F]FB-IL2 reached highest uptake in this species 
within 15 min after tracer injection, whereas most of 
the tracer was already cleared from the body at 60 min 
[23]. This shows that [18F]FB-IL2v has slower clearance 
kinetics in immune-competent Balb/c mice than wild-type 
IL2. The difference in kinetic profile between mutant [18F]
FB-IL2v and wild-type [18F]FB-IL2 may be related to 
the reduced binding affinity of [18F]FB-IL2v to CD25 on 
circulating immune cells and or vascular cells e.g. in the 
lung endothelium [27–28]. This would suggest that CD25 
expressing (immune) cells may be actively involved in 
the clearance, internalization and degradation of IL2. This 








0.40 ± 0.20 10.6 ± 2.9 0.47 ± 0.02 50.1 ± 3.7 0.7 ± 0.2 (17 %)
7.1 ± 2.6 
(83%)
Mutant [18F]FB-IL2v
0.18 ± 0.04 4.3 ± 0.5 0.21 ± 0.01 40.7 ± 1.9 2.1 ± 1.3 (14%)
17.6 ± 1.3 
(86%)
p < 0.01 p < 0.001 p < 0.01 p < 0.05 NS p < 0.01
Mutant [18F]FB-IL2v + 
5 mg/kg wild-type IL2 0.07 ± 0.02 2.2 ± 0.7 0.10 ± 0.01 31.7 ± 0.4 1.1 ± 0.6 (14%)
38.2 ± 1.6 
(86%)
p < 0.001 p < 0.001 p < 0.001 p < 0.05 NS p < 0.01
Bi-exponential clearance of the tracer was observed in plasma. The data represent the mean ± standard deviation.
Figure 5: Pharmacokinetic profiles of wild type [18F]FB-IL2 and mutant [18F]FB-IL2v. Wistar rats were inoculated in the 
shoulder with 107 PHA activated human PBMCs. Animals were injected with wild type [18F]FB-IL2 (n = 6) or mutant [18F]FB-IL2v (n = 4) 
and a 60-min dynamic PET scan with blood sampling was acquired. In addition, Wistar rats (n = 4) were pretreated with wild-type IL2 
(5 mg/kg, S.C) 30 min before injection of mutant [18F]FB-IL2v to assess whether tracer uptake is specifically mediated by the IL2 receptor. 
The time activity curves of (A) metabolite corrected plasma and (B) the PBMC implant. All data represents the mean ± SD. Statistical 
significant difference are represented by *(p < 0.05).
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hypothesis is in line with our PET imaging results, which 
showed that the clearance of mutant [18F]FB-IL2v from 
immune-deficient SCID mice was substantially slower 
than from immune-competent Balb/c mice. A similar 
effect was previously also observed for wild-type [18F]
FB-IL2 [23].
In order to prove that [18F]FB-IL2v binds to the 
activated human PBMCs in-vivo a PET imaging study 
in immune-deficient SCID mice was performed. Since 
these mice do not have any immune cells, one can neglect 
the effect of host immune cell interaction with [18F]FB-
IL2v. Therefore, mice were implanted with PHA activated 
human PBMCs to determine whether [18F]FB-IL2v 
specifically binds to IL2 receptors on activated immune 
cells pretreatment with either unlabeled wild-type IL2 
or mutant IL2v significantly reduced tracer uptake in 
the implants by 70 % and 55 %, respectively, suggesting 
specific binding to human IL-2 receptors. However, 
pretreatment with wild-type IL2 or mutant IL2v not only 
reduced the uptake in the implant, but also affected the 
clearance rate of [18F]FB-IL2v from non-target tissues. 
The reduction in tracer uptake in the implant can therefore 
not with certainty be ascribed to inhibition of specific 
binding of the tracer to IL2 receptors. Similar result were 
obtained for wild-type [18F]FB-IL2 in a previous study 
by Gialleonardo et al. [23]. In contrast to the results in 
SCID mice, pretreatment with unlabeled IL2 in Wistar 
rats showed a significant inhibition of mutant [18F]FB-
IL2v accumulation in the implant, but not in non-target 
organs, indicating that tracer accumulation in the implant 
is due to specific binding to the IL2 receptor. Interestingly, 
pretreatment of Wistar rats with wild-type IL2 reduced 
the rate of plasma clearance of mutant [18F]FB-IL2v (i.e. 
increased the plasma half-life), but did not affect the rate 
of metabolism in plasma. Pretreatment with wild-type 
IL2 prevents binding of mutant [18F]FB-IL2v to the IL2 
receptor and thus increases the availability of the tracer in 
plasma. Alternatively, the excess of unlabeled wild-type 
IL2 might have competed with mutant [18F]FB-IL2v for its 
degradation and clearance by the kidneys or immune cells. 
In order to compare the binding and kinetic 
properties of wild-type [18F]FB-IL2 and mutant [18F]FB-
IL2v, a quantitative kinetic modeling study was performed 
in immune-competent Wistar rats inoculated with PHA-
activated human PBMCs. Compartment modeling showed 
that [18F]FB-IL2v kinetics could be fitted better by the 
2TRCM than the 1TCM, which is in agreement with 
reversible receptor binding of the radiopharmaceutical. 
Similar results were previously observed for wild-type 
[18F]FB-IL2 by di Gialleonardo et al. [24]. The reversible 
binding properties of the radiopharmaceutical were 
confirmed by graphical analysis, as tracer kinetics could 
be well described by Logan graphical analysis, but not by 
Patlak graphical analysis. Compartmental analysis with 
the 2TRCM and Logan graphical analysis were used to 
calculate the BPnd and VT of the labeled proteins. Both 
compartment modeling and Logan analysis showed that 
both the VT and the BPnd of mutant [
18F]FB-IL2v were 
3-fold lower than those of wild-type [18F]FB-IL2. The 
reduced binding of mutant [18F]FB-IL2v can be ascribed 
to the three mutations in its binding domain that results 
in complete abolishment of CD25 binding. Still, mutant 
IL2v has retained binding affinity to the β subunit of the 
IL2 receptor, which is responsible for the specific binding 
of the mutant tracer in the implant [20–21]. 
Taken together, these imaging studies in different 
rodent species demonstrated that mutant IL2v has 
lower binding affinity for the high affinity IL2R and 
consequently slower plasma kinetics than wild-type IL2. 
These properties would be beneficial if mutant IL2v 
would be used as a therapeutic drug e.g. when fused to 
an antibody in an immunocytokine to enable preferential 
tumor cell targeting over systemic immune cell targeting. 
The slower plasma half-life would allow less frequent 
administration of the mutant IL2v protein. Moreover, the 
mutated protein no longer binds to the α subunit of the IL2 
receptor and thus does not activate CD4+CD25+Foxp3+ 
lymphocytes. Thus, cytotoxic T cells will not convert into 
Treg cells and retain their therapeutic efficacy. Obviously, 
further investigation of mutant IL2v as a potential 
immunotherapeutic agent is still required.
MATERIALS AND METHODS
All reagents and chemicals were obtained from 
the commercial suppliers and used without further 
purification. HPLC analyses were performed on a 
Waters system, consisting of a 515-isocratic pump, a 
multi-wavelength UV detector operated at 280 nm and 
a Bicron Geiger–Müller radioactivity detector. Quality 
control was performed by Ultra-high performance liquid 
chromatography (UPLC), using a Waters Acquity UPLC 
H-class system, equipped with a BEH shield RP18 column 
(1.7 µm, 3 × 50 mm) and a Berthold Flowstar LB 513 
radioactivity detector. 
Labeling of [18F]FB-IL2v
The synthesis of [18F]FB-IL2v was carried out as 
described in the literature for the labeling of wild-type [18F]
FB-IL2 [23], but with some modifications. The production 
of the synthon N-succinimidyl-4-[18F]ﬂuorobenzoate 
([18F]SFB) was carried using a Zymark robotic system as 
described before [23]. [18F]SFB was purified by HPLC 
using a Luna C18 column (250 × 15 mm, Phenomenex) 
and 40% aqueous ethanol supplemented with 0.1% 
trifluoroacetic acid (TFA) as the eluent at a flow rate of 3 
ml/min. The radioactive peak with a retention time of 10 ± 
1 min was collected and diluted with 20 ml of water. The 
diluted product was trapped on an Oasis HLB 30 mg (1 cc) 
cartridge (Waters) and the cartridge was washed with 
10 ml of water and eluted with 5 ml of diethyl ether 
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to obtain pure [18F]SFB. The solvent was evaporated 
with a nitrogen flow at 50°C. A mixture consisting of 
100 µl of TRIS buffer (50 mM, pH 8.5), 100 µl of ethanol 
and 100 µl of IL2v (200 µg in nitrogen purged water) was 
added to the vial containing the purified [18F]SFB. The 
reaction mixture was incubated at 50°C for 10 min. After 
incubation, the product was purified by passing the reaction 
mixture through a PD-10 Sephadex G-25 size-exclusion 
cartridge (GE healthcare). Before use, the PD-10 cartridge 
was conditioned by elution with ~20 ml elution buffer, 
consisting of phosphate-buffered saline (PBS) supplemented 
with 0.05 % sodium dodecylsulfate (SDS) and 0.5 % human 
serum albumin (HSA). The labeled protein was eluted from 
the cartridge with elution buffer and collected in 15 fractions 
of 0.5 ml. The fractions that contained pure [18F]FB-IL2v 
were pooled and used for in-vitro and in-vivo experiments. 
In-vitro quality controls
The quality control of [18F]FB-IL2v was carried out 
by three methods: UPLC, radio-TLC and the trichloracetic 
acid (TCA) precipitation assay. UPLC was performed 
by gradient elution at a flow rate of 0.8 ml/min, using a 
mixture of 0.1% aqueous TFA (solvent A) and 0.1% TFA 
in acetonitrile (solvent B), according to the following 
gradient profile: 0–1 min, 5% solvent B, 1–4 min, 30% 
solvent B, 4–8 min, 50% solvent B, 8–13 min, 70% 
solvent B, and 13–15 min, 5% solvent B. The radioactive 
peak that eluted at 9.6 min corresponded with [18F]FB-
IL2v, the peak at 5.0 min with [18F]SFB, and the peak at 
4.0 min with 4-[18F]fluorobenzoic acid ([18F]FBA). Radio-
TLC was performed with Merck F-254 silica gel plates as 
described in the literature [23]. 
To determine the percentage protein-bound 
radioactivity, a TCA precipitation assay was performed. 
Labeled protein was precipitated by adding 20% ice-
cold TCA and 5 µl of 20% HSA. The suspension was 
centrifuged at 3000 rpm for 5 min. Half of the clear 
supernatant was removed and placed in a clean tube. 
The activity in both tubes was measured in a gamma 
counter (Compugamma CS1282, LKB-Wallac, Turku, 
Finland), and the percentage of labeling was determined 
using the formula: percentage of protein-bound activity 
(%) = {[Activity (tube pellet + supernatant)–Activity 
(tube supernatant)]/[Activity (tube pellet + supernatant) + 
Activity (tube supernatant)]} × 100%. 
Protein concentration 
The protein concentration in the [18F]FB-IL2v 
solution was determined by spectrophotometric analysis 
using a cuvette-free NanoDrop spectrophotometer (N-
1000 Spectrophotometer; Thermo Fisher Scientific Inc). 
An estimation of the protein concentration was obtained 
by measuring the UV absorption at 280 nm.
 In-vitro stability 
In-vitro stability of [18F]FB-IL2v was tested both in 
saline and rat plasma. The tracer was incubated at 37°C 
and samples were collected at different time points (0, 15, 
30, 60, and 90 min). The samples were analyzed by radio-
TLC and the TCA precipitation assay as described above. 
All experiments were performed in triplicate (n = 3).
In-vitro binding 
In order to check the binding of mutant [18F]
FB-IL2v to the IL2 receptors, a binding assay was 
carried out using human PBMCs. PBMCs were 
activated by incubating phytohemagglutinin (PHA; 
10 μg/ml; Sigma) in the presence of gentamicin 
(125 μg/ml; Gibco BRL). Either activated or non-
activated hPBMCs in RPMI-1640 complete medium 
supplemented with 0.05% bovine serum albumin were 
seeded in 12-well plates (0.5 × 106 cells/well) [25–26]. 
Approximately 500 kBq of mutant [18F]FB-IL2v was 
added to each well and the cells were incubated at 37°C. 
After 30 min, the cells were washed twice with 1 ml of 
ice-cold PBS and cell-bound radioactivity was measured 
in a gamma counter. The radiopharmaceutical uptake was 
corrected for the number of viable cells. Thus, cells were 
counted manually using the Trypan blue method. Uptake 
was expressed as %ID/106 cells. All experiments were 
carried out in triplicate (n = 3). In blocking experiments, 
cells were incubated with either wild type IL2 or mutant 
IL2v (2 ng/ml) at 4°C, 30 min prior to administration of 
[18F]FB-IL2v.
Animals
All animal experiments were performed according 
to the Dutch regulations on animal welfare; the protocol 
was approved by the Institutional Animal Care and Use 
Committee of the University of Groningen (protocol: 
DEC6608A). All animals were allowed 1 week of 
acclimation after arrival. Animals were maintained at 12 h 
day/12 h night regime and fed standard laboratory chow.
Ex-vivo biodistribution in Balb/c mice
Ex-vivo biodistribution was carried out in healthy 
male Balb/c mice (Harlan) with a body weight of 18–22 
g. Animals were anaesthetized with 2% isoflurane in 
medical air and injected with 1–4 MBq (20–80 ηg) of 
mutant [18F]FB-IL2v through the penile vein and kept 
under anesthesia. After 15, 60 and 90 min, animals were 
sacrificed and relevant organs were excised and weighed 
(n = 5 for each time point). Radioactivity in different 
organs was measured using an automatic gamma counter 
and expressed as standardized uptake values (SUV). 
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PET imaging 
In-vivo imaging experiments were performed in 20–
22 g male SCID mice (Harlan) with an implant of human 
PBMCs (n = 4). Sixty minutes before tracer injection, 107 
PHA-activated human PBMC cells in 300 µL of a mixture 
of Matrigel® and medium (1:1) were subcutaneously 
implanted in the right shoulder of the SCID mice. The 
mice were anesthetized with isoflurane in medical air (5% 
for induction, 2% for maintenance) and 6 ± 2 MBq (120 
± 40 ηg) of mutant [18F]FB-IL2v was injected via the tail 
vein. Mice were positioned in the PET camera (Micro-PET 
Focus 220, Siemens-Concorde) and a 30-min dynamic 
emission scan was performed, followed by a 15-min 
transmission scan with a cobalt-57 point source to correct 
for attenuation and scatter. After completion of the scan, 
the animals were terminated and implants of PBMCs were 
excised and radioactivity was measured using a gamma 
counter. Tracer uptake was expressed as SUV.
In order to investigate the specific binding of the 
mutant [18F]FB-IL2v, mice were pre-treated with either 
unlabeled wild-type IL2 or unlabeled mutant IL2v (5 mg/kg, 
S.C, n = 4) 30 min before the radiopharmaceutical 
injection. Imaging was performed as described above.
Dynamic PET imaging with arterial blood 
sampling
Male Wistar rats (270–340 g, Harlan, n = 6) were 
anaesthetized with mixture of isoflurane and medical air 
(5% for induction, 2% for maintenance). Cannulas were 
inserted in the femoral artery for rapid blood sampling 
and in the femoral vein for radiopharmaceutical injection. 
A mixture of 107 PHA-activated human PBMCs in 
Matrigel®-medium (1:1) was inoculated into the right 
shoulder of the animals 60 min before radiopharmaceutical 
injection. PET experiments were performed by scanning 
2 rats simultaneously. The animals were positioned in the 
PET camera with their implants in the field of view. A 15-
min transmission scan was performed to correct for scatter 
and attenuation. After the transmission scan, 15 ± 3 MBq 
(300 ± 50 ηg) of mutant [18F]FB-IL2v in 1 ml was injected 
as a slow bolus injection (1 ml/min) using a Harvard-style 
pump. A dynamic PET scan was started as soon as the 
radiopharmaceutical entered the body of the first animal. 
The second animal was injected 16 min later. PET data 
were reconstructed separately for both animals to generate 
a 60-min dynamic PET scan for each animal. A series of 
arterial blood samples (~0.1 ml) were collected from each 
animal during the scan at approximately 10, 20, 30, 40, 50, 
60, 90, 120, 180, 300, 450, 600, 900, 1800 and 3600 s after 
radiopharmaceutical injection. To prevent large changes in 
blood pressure, 0.1 ml of heparinized saline was injected 
after collection of each sample. A 25 µL sample of whole 
blood was collected. Plasma was separated from the 
remainder of the blood sample by centrifugation (3000 
rpm for 5 min) and a 25 µL plasma sample was taken 
from the supernatant. Radioactivity in both whole blood 
and plasma samples was measured and used to generate 
input curves for kinetic modeling.
To study the specific binding of mutant [18F]FB-
IL2v, rats were injected with unlabeled wild-type IL2 
(5 mg/kg, S.C) 30 min before radiopharmaceutical 
injection (n = 4). PET acquisition and blood sampling was 
performed as described above. After completion of the 
emission scans, the animals were terminated and different 
tissues were collected and radioactivity was measured 
using a gamma counter. 
A group of rats (n = 4) was injected with 
radiolabeled wild-type IL2 ([18F]FB-IL2) to allow head-to-
head comparison of the binding potential and kinetics of 
radiolabeled wild-type IL2 with mutant IL2v. The scanning 
and sampling protocol was identical to the procedure 
described above. Rats were terminated at the end of the 
scan and ex-vivo biodistribution was carried out (80 min 
after radiopharmaceutical injection). Different organs 
were collected and uptake of the radiopharmaceutical was 
measured in a gamma counter. 
 In-vivo metabolite analysis 
To analyze the presence of metabolites of mutant 
[18F]FB-IL2v in plasma of Wistar rats with a hPBMCs 
implant, blood samples collected at 5, 10, 20, 30 and 60 
min after tracer injection were centrifuged and the clear 
supernatant (plasma) was collected. The percentage of 
intact tracer in plasma and urine samples was determined 
by TCA precipitation as described above.
Image reconstruction
All the emission scans were normalized and 
corrected for scatter, attenuation and decay of radioactivity. 
Emission sinograms were iteratively reconstructed 
(OSEM2D, 16 subsets, 4 iterations). List mode data of 
the emission scans of Wistar rats were separated into 21 
frames (6 × 10, 4 × 30, 2 × 60, 1 × 120, 1 × 180, 4 × 300, 
3 × 600 s). List mode data of the emission scans of SCID 
mice were separated into 6 frames (6 × 300 s). A three-
dimensional volume of interest (VOI) was manually drawn 
around the implant on the summed PET images (0–60 min 
for Wistar rats, 0–30 min for SCID mice) using Inveon 
Research Workplace software (Inveon, Siemens, USA). 
The resulting VOIs were used on the original data set to 
create the corresponding time-activity curves (TACs) and 
to calculate standardized uptake values (SUV).
Kinetic analysis
Compartment modeling and graphical analysis 
of tracer kinetics in the implants of Wistar rats were 
carried out using the Inveon software package. Different 
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compartmental models were used to fit the TACs 
generated from the VOIs in order to determine the kinetic 
rate constants. The best model was selected based on 
the Akaike information criterion (AIC) values. Logan 
and Patlak graphical analysis were used to determine 
whether the kinetics of the radiopharmaceuticals can be 
described by reversible or irreversible binding models. 
Volume of distribution (VT) as well as non-displaceable 
binding potential (BP
ND
) were determined. The metabolite-
corrected plasma curve was used as an input function. The 
whole blood curves were used for blood volume correction.
Statistical analysis
Statistical analyses were performed using the 
GraphPad prism 5. All data are expressed as mean ± 
standard deviation. The unpaired two-sided student’s 
t-test was used to determine the significance of differences 
between groups. Probability (p) values less than 0.05 were 
considered statistically significant.
CONCLUSIONS 
Our data suggest that there is a significant 
difference in binding properties and plasma kinetics 
between mutant [18F]FB-IL2v and wild-type [18F]FB-
IL2. Wild-type [18F]FB-IL2 shows stronger binding to 
the IL2 receptor and faster plasma clearance than [18F]
FB-IL2v. It seems that binding of the labeled protein to 
circulating immune cells can strongly affect the plasma 
clearance of the protein. The faster clearance and higher 
binding affinity make wild-type [18F]FB-IL2 better suited 
as a PET imaging probe for activated T cells. On the 
other hand, mutant [18F]FB-IL2v, seems to have better 
kinetic properties for a therapeutic agent. Future studies 
to evaluate the potential of mutant IL2v as an anti-tumor 
agent are ongoing.
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